Joint Department of Medical Imaging, University Health Network/Mount Sinai Hospital/Women's College Hospital, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Laboratory Medicine Program, Department of Pathology, Toronto General Hospital, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Abdom Radiol (NY). 2021 Apr;46(4):1572-1585. doi: 10.1007/s00261-020-02821-y. Epub 2020 Oct 19.
To assess the imaging findings of hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT) as a bridging therapy prior to liver transplantation (LT), with histopathological correlation at liver explant.
Our institutional review board approved this retrospective study. The study subjects included 25 HCC lesions in 23 patients (20 males; median age, 60 years; range 41-68 years) who underwent LT after SBRT for HCC as a bridge to LT in a single tertiary referral institution over a 12-year period. Target HCC lesions were assessed for imaging biomarkers on contrast-enhanced CT or MRI including change in HCC diameter and assessment of percentage necrosis. The radiologic response at pre-LT imaging was compared to explant pathology.
There was a positive correlation between the tumor size (Spearman's ρ = 0.86; p < 0.001) and percentage necrosis (p < 0.001) on Pre-LT imaging and those on pathology. Partial response (PR), stable disease (SD), and progressive disease (PD) according to RECIST 1.1 were seen in 8 (32%), 15 (60%), and 2 (8%) lesions on pre-LT imaging, respectively. Of the 15 lesions with radiologic SD, 5/15 (33%) showed necrosis of more than 50% on post-SBRT imaging, while 9/15 (60%) showed necrosis of more than 50% at explant pathologic analysis, showing a tendency to underestimate the degree of tumor necrosis compared to pathology.
RECIST 1.1 radiologic response criteria may underestimate the response to treatment with SBRT, and radiologic estimation of percent tumor necrosis was more closely correlated with pathologic percent tumor necrosis.
通过与肝移植(LT)时的组织病理学结果进行相关性分析,评估立体定向体放射治疗(SBRT)桥接治疗后肝细胞癌(HCC)的影像学表现。
本回顾性研究经机构审查委员会批准。研究对象为 12 年间在一家三级转诊机构接受 SBRT 桥接治疗后行 LT 的 23 例患者(20 例男性;中位年龄 60 岁;范围 41-68 岁)的 25 个 HCC 病灶。在增强 CT 或 MRI 上评估 HCC 病灶的影像学生物标志物,包括 HCC 直径的变化和坏死百分比的评估。将 LT 前影像学上的放射学反应与肝移植标本的组织病理学结果进行比较。
在 LT 前的影像学和组织病理学上,肿瘤大小(Spearman's ρ = 0.86;p < 0.001)和坏死百分比(p < 0.001)之间存在正相关。根据 RECIST 1.1 标准,在 LT 前的影像学上,分别有 8 个(32%)、15 个(60%)和 2 个(8%)病灶显示完全缓解(PR)、疾病稳定(SD)和疾病进展(PD)。在 15 个 SD 病灶中,有 5/15(33%)个病灶在 SBRT 后显示出 50%以上的坏死,而在 15 个病灶中,有 9/15(60%)个病灶在组织病理学检查中显示出 50%以上的坏死,与病理学结果相比,显示出低估肿瘤坏死程度的趋势。
RECIST 1.1 影像学反应标准可能低估了 SBRT 的治疗反应,而影像学估计的肿瘤坏死百分比与病理学肿瘤坏死百分比更密切相关。